Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 15/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 14/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211058 | 0.95 | PDGFRB (0.47) | EHMT2EHMT1KDRMET | |
| SCHEMBL4686452 | 0.90 | EHMT2 (0.61) | EHMT2EHMT1KDRSPIN1 | |
| SCHEMBL2924579 | 0.89 | EHMT2 (0.60) | EHMT2EHMT1KDRSPIN1 | |
| SCHEMBL4025116 | 0.89 | EHMT2 (0.52) | EHMT2EHMT1KDRMETDNMT1 | |
| SCHEMBL829762 | 0.87 | KDM1A (0.57) | KDRMETKDM1A | |
| SCHEMBL1734721 | 0.87 | KDM1A (0.57) | KDRMETKDM1A | |
| SCHEMBL29478513 | 0.87 | KDM1A (0.57) | KDRMETKDM1A | |
| SCHEMBL29478512 | 0.87 | KDM1A (0.57) | KDRMETKDM1A | |
| Hydrochloric Acid SCHEMBL4378504 | 0.86 | KDM1A (0.56) | KDRMETKDM1A | |
| Hydrochloric Acid SCHEMBL27988356 | 0.86 | KDM1A (0.56) | KDRMETKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | claimed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | claimed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | EHMT2 2872/4885EHMT1 2444/4885KDR 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.